GrowthHormone Research Society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome.

What It Covers

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a systematic review.

The aim of the study was to formulate recommendations for the use of rhGH in children and adult patients with PWS.

Why It Was Studied

Recombinant human GH (rhGH) therapy in Prader-Willi syndrome (PWS) has been used by the medical community and advocated by parental support groups since its approval in the United States in 2000 and in Europe in 2001.

The researchers performed a systematic review of the clinical evidence in the pediatric population, including randomized controlled trials, comparative observational studies, and long-term studies (>3.5 y).

Who the Included Studies Covered

By PubMed's age tags, the people studied were infants, children and adults.

Forty-three international experts and stakeholders followed clinical practice guideline development recommendations outlined by the AGREE Collaboration (www.agreetrust.org).

Evidence was synthesized and graded using a comprehensive multicriteria methodology (EVIDEM) (http://bit.ly.PWGHIN).

What Was Measured

PubMed files the paper under topics including Human Growth Hormone, Practice Guidelines as Topic, Prader-Willi Syndrome and Recombinant Proteins.

What This Means in Plain Language

This is a systematic review of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2013 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.